Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Joshua Rosenblat
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07569198CT.gov Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | — | Not Yet Recruiting | — | — | — |
NCT05004896CT.gov Ketamine for Treatment-Resistant Bipolar Disorder | — | Completed | — | — | — |
NCT04939649CT.gov Ketamine As an Adjunctive Therapy for Major Depression (2) | — | Completed | — | — | — |
NCT03256162CT.gov Ketamine as an Adjunctive Therapy for Major Depression | — | Completed | — | — | — |
NCT02593643CT.gov Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Depression
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midazolam (this asset) | Joshua Rosenblat | P3 | BB · 68 |
| Lurasidone | NeuroRx, Inc. | P4 | A |
| Lithium, Elemental | Dr. Inge Winter | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Joshua Rosenblat | P4 | BBB |
| Quetiapine | Dr. Inge Winter | P4 | BBB |
| Lamotrigine | Stony Brook University | P4 | BBB |
| Nrx-101 | NeuroRx, Inc. | P3 | BBB |
| Escitalopram | Dr. Inge Winter | P4 | BBB |
| Sertraline | Dr. Inge Winter | P4 | BB |
+42 more in the Bipolar Depression cohort
Other indications for Midazolam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuralgia | — | P4 | BBB · 75 |
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 75 |
| Choledocholithiasis | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midazolam in Bipolar Depression. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midazolam-bipolar-depression
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →